Teva Pharmaceuticals dedicated its new research and development center in Rehovot at an investment of NIS 15m., the generic drug maker said Tuesday.
The new facility will form part of Teva's biogenerics group, and its R&D line-up which includes generics, chemicals, and biotechnology, will have a research team of over 20 high ranking scientists working there. Teva said it currently has over 800 employees in R&D in Israel alone.
Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>